Ansbert Gadicke - 04 Jan 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Footnote F1

BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Footnote F2

The shares were sold as follows: 56,414 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,959 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 35,653 by MPM BioVentures 2018, L.P. ("BV 2018"), 719 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 63,834 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The shares are held as follows: 1,575,558 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 54,213 by AM BV2014, 995,065 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 19,634 by AM BV2018 and 1,780,893 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Footnote F5

The shares were sold as follows: 11,534 by BV 2014, 390 by AM BV2014, 7,300 by BV 2018, 142 by AM BV2018 and 13,030 by UBS Oncology.

Footnote F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F7

The shares are held as follows: 1,564,024 by BV 2014, 97,289 by BV 2014(B), 53,823 by AM BV2014, 987,765 by BV 2018, 48,966 by BV 2018(B), 19,492 by AM BV2018 and 1,767,863 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Footnote F8

The shares were sold as follows: 4,050 by BV 2014, 133 by AM BV2014, 2,544 by BV 2018, 41 by AM BV2018 and 4,550 by UBS Oncology.

Footnote F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F10

The shares are held as follows: 1,559,974 by BV 2014, 97,289 by BV 2014(B), 53,690 by AM BV2014, 985,221 by BV 2018, 48,966 by BV 2018(B), 19,451 by AM BV2018 and 1,763,313 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Footnote F11

The shares were sold as follows: 4,590 by BV 2014, 154 by AM BV2014, 2,874 by BV 2018, 53 by AM BV2018 and 5,158 by UBS Oncology.

Footnote F12

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.025 to $46.965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F13

The shares are held as follows: 1,555,384 by BV 2014, 97,289 by BV 2014(B), 53,536 by AM BV2014, 982,347 by BV 2018, 48,966 by BV 2018(B), 19,398 by AM BV2018 and 1,758,155 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Footnote F14

The shares were sold as follows: 10,804 by BV 2014, 372 by AM BV2014, 6,824 by BV 2018, 135 by AM BV2018 and 12,212 by UBS Oncology.

Footnote F15

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F16

The shares are held as follows: 1,544,580 by BV 2014, 97,289 by, 53,164 by AM BV2014, 975,523 by BV 2018, 48,966 by BV 2018(B), 19,263 by AM BV2018 and 1,745,943 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.